Related Experiment Video
Updated: Jul 2, 2026
10:01
Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach
Published on: June 23, 2026
The Protein kinase inhibitor balanol: structure-activity relationships and structure-based computational studies
Vineet Pande1, Maria J Ramos, Federico Gago
1Departamento de Farmacología, Universidad de Alcalá, Alcalá de Henares, 28871 Madrid, Spain.
Anti-Cancer Agents in Medicinal Chemistry
|August 12, 2008
Summary
Balanol, a fungal metabolite, inhibits Protein Kinase A (PKA) and Protein Kinase C (PKC). Research explores balanol analogs for cancer therapy, using structural and computational methods to understand binding and improve drug design.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Structural Biology
Background:
- Balanol, a fungal metabolite, is a potent inhibitor of Protein Kinase A (PKA) and Protein Kinase C (PKC).
- These kinases are critical targets in cancer therapy.
- Since 1993, efforts have focused on developing selective and bioavailable balanol analogs.
Purpose of the Study:
- To provide an overview of structure-activity relationships for balanol analogs.
- To summarize progress in structural and computational studies of balanol.
- To highlight the utility of the PKA-balanol complex in structure-based drug design.
Main Methods:
- Analysis of structure-activity relationships (SAR) of balanol analogs.
- Review of crystal structures of PKA complexed with balanol and analogs.
- Examination of computational methodologies for ligand binding and protein flexibility.
Main Results:
- Key interactions for PKA-balanol binding have been elucidated through crystal structures.
- The PKA-balanol complex serves as a model for structure-based ligand design.
- Computational studies have advanced understanding of molecular recognition and protein flexibility.
Conclusions:
- Structural and computational studies provide valuable insights into balanol analog design.
- Further development of balanol analogs holds promise for oncology targets like PKA and PKC.
- Understanding protein-ligand interactions is crucial for optimizing drug candidates.
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:24Protein Organization
Proteins are polymers of amino acid residues. They are versatile and responsible for different cellular functions, including DNA replication, molecular transport, catalysis, and structural support. Proteins have a hierarchical structure comprising at least three levels of organization: primary, secondary, and tertiary structure. Some large proteins have a quaternary structure where individual protein subunits are linked together.
The primary structure of a protein is its amino acid sequence.
The primary structure of a protein is its amino acid sequence.
02:04Protein-protein Interfaces
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a polypeptide...
02:18The Equilibrium Binding Constant and Binding Strength
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
01:16Protein-Drug Binding: Mechanism and Kinetics
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
02:40Ligand Binding Sites
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...